SCHEMBL23217177

SCHEMBL23217177

CCOC(=O)CC(=O)C[C@@H]1C[C@H](c2c(OC)ccc(Cl)c2Cl)CN1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.39
HTR2C P28335 4/20 0.39
HTR2B P41595 4/20 0.39
ALDH1A1 P00352 5/20 0.34
KDM4E B2RXH2 5/20 0.34
GAA P10253 3/20 0.34
HSD17B10 Q99714 3/20 0.34
PDE4D Q08499 2/20 0.34
PKM P14618 1/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
LMNA P02545 4/20 0.33
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
DRD2 P14416 1/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
CYP2C9 P11712 3/20 0.32
CYP1A2 P05177 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29844903 1.00 HTR2A (0.39) HTR2AHTR2CHTR2BALDH1A1KDM4E
SCHEMBL23217482 0.78 HTR2A (0.38) HTR2AHTR2CHTR2BALDH1A1KDM4E
SCHEMBL23227264 0.78 HTR2C (0.49) HTR2AHTR2CHTR2B
Hydrochloric Acid SCHEMBL23217143 0.77 HTR2C (0.50) HTR2AHTR2CHTR2B
Hydrochloric Acid SCHEMBL29845008 0.77 HTR2C (0.50) HTR2AHTR2CHTR2B
SCHEMBL23217319 0.77 DRD2 (0.38) HTR2AHTR2CHTR2BALDH1A1KDM4E
SCHEMBL23239723 0.76 HTR2A (0.43) HTR2AHTR2CHTR2BDRD2ADRA1A
SCHEMBL29885848 0.76 HTR2A (0.43) HTR2AHTR2CHTR2BDRD2ADRA1A
SCHEMBL23216481 0.76 HTR2A (0.43) HTR2AHTR2CHTR2BDRD2ADRA1A
SCHEMBL23227278 0.75 SRC (0.37) HTR2AHTR2CHTR2BALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-02-16 US disclosed
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-02-16 US disclosed
EP-4041405-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. Shaw Research, LLC (US) 2022-08-17 EP disclosed
WO-2021071832-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed
WO-2021071832-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNB1, KCNJ2, KCNB2 HTR2A 1799/4885HTR2C 1162/4885HTR2B 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.